Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
Cadrenal Therapeutics received FDA guidance for a pivotal Phase 3 trial of CAD-1005 in HIT after an End-of-Phase 2 meeting. Phase 2 data showed a >25% absolute reduction in thrombotic events. The company also plans a Phase 2a trial in cardiac surgery-associated AKI.
The phase 3 OCEANIC-STROKE trial of 12,327 patients showed asundexian, an oral Factor XIa inhibitor, reduced ischemic stroke recurrence by 26% when added to standard antiplatelet therapy, with no increase in major bleeding events.
